Welcome to our dedicated page for NK news (Ticker: NK), a resource for investors and traders seeking the latest updates and insights on NK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NK's position in the market.
NantKwest (NASDAQ: NK) and ImmunityBio have announced a merger agreement that will create a leading immunotherapy and cell therapy entity focused on oncology and infectious diseases. The merger combines their extensive clinical-stage pipeline, featuring 13 clinical assets and 11 in advanced phases, leveraging NantKwest’s natural killer cell platform and ImmunityBio’s immunotherapy technologies. ImmunityBio’s Anktiva, with Breakthrough Therapy status, shows a 72% complete response rate in bladder cancer. The merger is structured as a tax-free stock-for-stock transaction, with ImmunityBio shareholders expected to own 72% of the new entity.
ImmunityBio announced successful results from a challenge study of its hAd5-COVID-19 vaccine candidate, showing complete protection against SARS-CoV-2 in non-human primates. The study, backed by BARDA, demonstrated that the vaccine inhibited viral replication in all tested Rhesus macaques, with undetectable levels of the virus observed within days. The innovative approach targets both spike and nucleocapsid proteins, enhancing immune response and potentially reducing reinfection rates. The oral formulation of the vaccine is set to enter Phase I trials, aiming to simplify distribution amid logistical challenges.
ImmunityBio announced the publication of preclinical data in Cancer Immunology, Immunotherapy highlighting Anktiva's efficacy in enhancing interferon-gamma production and tumor cell killing by NK cells. The results show that Anktiva stimulates HPC-NK cell proliferation and improves their function against various cancers, including leukemia and ovarian cancer. Anktiva, currently in late-stage trials alongside NantKwest's NK cell therapies, is positioned to advance cancer treatment by leveraging IL-15 superagonism, with significant potential across multiple solid tumors.
NantKwest, Inc. (NASDAQ: NK) will participate in the virtual 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020. Executive Chairman Patrick Soon-Shiong, M.D., and CEO Rich Adcock will lead investor meetings on December 1, with access to a pre-recorded fireside chat starting November 23, available on the Piper Sandler site and NantKwest's website until December 31, 2020. NantKwest specializes in natural killer cell therapies targeting cancer and infectious diseases, with clinical trials conducted in multiple regions.
NantKwest (NASDAQ: NK) and ImmunityBio have initiated a Phase 1 trial for their second-generation hAd5 COVID-19 vaccine candidate. Administered at Hoag Hospital, the trial involved 20 volunteers, with no serious adverse events reported in the low dose cohort. The vaccine uniquely targets both spike and nucleocapsid proteins, aiming to elicit robust T cell and antibody responses for long-term immunity. The trial aims to assess safety and immune response, with further participant enrollment ongoing.
ImmunityBio announced positive results for its Ad5 COVID-19 vaccine that induces memory T-cell responses in patients previously infected with SARS-CoV-2. This dual-action vaccine targets the virus's spike and nucleocapsid proteins, potentially offering long-term immunity as antibodies wane. The study suggests the vaccine could protect uninfected individuals and aid viral clearance in infected patients. The company is currently enrolling participants for a Phase I clinical trial of the vaccine and exploring various administration methods. The findings are detailed in a preprint manuscript on medRxiv.
NantKwest (NASDAQ: NK) has appointed Richard Adcock as its new Chief Executive Officer, effective immediately. Adcock, with extensive experience in healthcare operations, succeeds Dr. Patrick Soon-Shiong, who will transition to Executive Chairman. Adcock previously led Verity Health Systems through a successful restructuring and has held significant roles at Sanford Health. This leadership change comes as NantKwest continues to advance its natural killer cell-based immunotherapies for cancer and infectious diseases, aiming to transform treatment protocols.
NantKwest (NASDAQ: NK) and ImmunityBio have initiated a Phase 1 clinical trial for hAd5-COVID-19, a novel COVID-19 vaccine targeting both the nucleocapsid and spike proteins of SARS-CoV-2. The trial aims to evaluate the vaccine's safety and reactogenicity in healthy adults aged 18 to 55. This second-generation adenovirus-based vaccine aims to stimulate both T-cell and antibody responses, potentially offering long-term immunity. The trial is being conducted at Hoag Hospital, Newport Beach, and is currently enrolling participants.
ImmunityBio has received FDA approval to initiate a Phase I clinical trial for its hAd5-COVID-19 vaccine, designed to target both the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2. This bivalent vaccine aims to achieve durable T-cell and antibody responses. The trial is set to begin this month at Hoag Hospital, involving adults up to 55 years old. ImmunityBio's innovative approach circumvents limitations of first-generation vaccines by enhancing immune memory and enabling repeated administrations. The company is also developing formulations for alternative routes of administration.
NantKwest (NASDAQ: NK) and ImmunityBio announced the addition of a third cohort to their ongoing Phase 2 trial investigating a novel immunotherapy for pancreatic cancer. This cohort allows patients who have exhausted all standard treatments to participate. The trial assesses a combination of PD-L1 t-haNK, IL-15 superagonist Anktiva, and aldoxorubicin against standard chemotherapy. Currently, 40 patients are enrolled across three active trial sites, aiming for a total of 298 subjects. The study's primary goal is to evaluate progression-free survival and overall survival in various treatment cohorts.
